[Limitation of adrenergic cardiovascular damage by exogenous infusion of a regulatory peptide dalargin].
Pashutin
S B
SB
D000208:Acute Disease; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001919:Bradycardia / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D004195:Disease Models, Animal; D016308:Enkephalin, Leucine-2-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004837:Epinephrine / Q000008:administration & dosage / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D066298:In Vitro Techniques; D007262:Infusions, Intravenous; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D000889:Anti-Arrhythmia Agents; D016308:Enkephalin, Leucine-2-Alanine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-; D004837:Epinephrine
Ogranichenie adrenergicheskogo povrezhdeniia serdechno-sosudistoĭ sistemy s pomoshch'iu ékzogennoĭ infuzii reguliatornogo peptida dalargina.